Bladex

BLXNYSEUSD

THESIS ALERT

Email me when the BLX thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$50.79
+$0.12 (+0.24%)Today 1M −6.17%
After hours$50.790.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$50.67
Prior regular-session close from the quote source.
$50.38–$50.97
Regular-session low and high so far today.
76.5K
Regular-session shares traded · Nov 11, 4:00 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$42.29–$63.20
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own BLX if its specialized Latin American trade-finance franchise can keep turning scarce U.S.-dollar funding and regional credit knowledge into profitable, well-capitalized loan growth after the current rate cycle normalizes.

BLX price history

Latest price$50.79Today+$0.12 (+0.24%)
BLX -6.38%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Latin American importers, exporters, and financial institutions continue to need specialized U.S.-dollar trade finance that Bladex can supply better than more generalist local banks or global banks with shifting regional appetite.StrengtheningMateriality: High

    IFRS total assets increased from $8.038 billion at FY2021 year-end to $11.859 billion at FY2024 year-end, consistent with continued balance-sheet deployment. If this demand channel holds, Bladex can keep deploying capital into earning assets; if clients migrate to cheaper or more stable funding alternatives, growth becomes much less valuable.

    Watch: Large global banks materially re-expand Latin American trade-finance books and win the same multinational and bank clients at lower spreads.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS total assets increased from $8.038 billion at FY2021 year-end to $11.859 billion at FY2024 year-end, consistent with continued balance-sheet.

    Open source ↗
  • Bladex’s ability to maintain ample U.S.-dollar liquidity is a core advantage because clients value dependable funding through regional liquidity cycles, not just headline loan pricing.StrengtheningMateriality: High

    IFRS cash and cash equivalents were $1.964 billion at FY2024 year-end versus $1.253 billion at FY2021 year-end. Liquidity is what allows Bladex to lend when competitors pull back; if funding access weakens, the franchise can shrink quickly even before credit losses appear.

    Watch: A ratings downgrade or country-risk shock raises Bladex’s wholesale dollar funding cost enough that trade-finance spreads no longer compensate for risk.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS cash and cash equivalents were $1.964 billion at FY2024 year-end versus $1.253 billion at FY2021 year-end.

    Open source ↗
  • Management must keep emerging-market credit risk disciplined enough that balance-sheet expansion does not turn into a credit-loss cycle.HoldingMateriality: Medium

    IFRS annual net income rose from $62.697 million in FY2021 to $205.873 million in FY2024, so recent growth has not yet been overwhelmed by credit costs in the reported bottom line. For a leveraged bank, a few bad country, sector, or borrower exposures can erase years of spread income and book-value growth.

    Watch: A concentrated borrower, bank counterparty, or country exposure in Latin America deteriorates before reserves are built.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS annual net income rose from $62.697 million in FY2021 to $205.873 million in FY2024, so recent growth has not.

    Open source ↗
  • The recent earnings step-up must prove to be more than a temporary benefit from higher interest rates; Bladex needs relationship-based pricing and funding discipline to preserve spreads as rates normalize.StrengtheningMateriality: Medium

    IFRS annual revenue increased from $99.157 million in FY2020 to $303.636 million in FY2024. If earnings are mostly rate-cycle windfall, the stock should be valued like a cyclical bank near peak profitability rather than a compounding franchise.

    Watch: Federal Reserve easing compresses asset yields faster than Bladex can lower funding costs.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS annual revenue increased from $99.157 million in FY2020 to $303.636 million in FY2024.

    Open source ↗
  • Bladex’s capital allocation must retain enough earnings to support a larger balance sheet while still returning excess capital to shareholders without weakening the bank.StrengtheningMateriality: Medium

    IFRS equity increased from $991.790 million at FY2021 year-end to $1.337 billion at FY2024 year-end. Owners benefit only if loan growth compounds per-share value; growth funded by excessive leverage or under-retention would increase fragility.

    Watch: Management pursues asset growth faster than capital generation, increasing leverage into a weaker credit cycle.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS equity increased from $991.790 million at FY2021 year-end to $1.337 billion at FY2024 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Latin American importers, exporters, and financial institutions continue to need specialized U.S.-dollar trade finance that Bladex can supply better than more generalist local banks or global banks with shifting regional appetite. If this demand channel holds, Bladex can keep deploying capital into earning assets; if clients migrate to cheaper or more stable funding alternatives, growth becomes much less valuable.

Bladex’s ability to maintain ample U.S.-dollar liquidity is a core advantage because clients value dependable funding through regional liquidity cycles, not just headline loan pricing. Liquidity is what allows Bladex to lend when competitors pull back; if funding access weakens, the franchise can shrink quickly even before credit losses appear.

Management must keep emerging-market credit risk disciplined enough that balance-sheet expansion does not turn into a credit-loss cycle. For a leveraged bank, a few bad country, sector, or borrower exposures can erase years of spread income and book-value growth.

The recent earnings step-up must prove to be more than a temporary benefit from higher interest rates; Bladex needs relationship-based pricing and funding discipline to preserve spreads as rates normalize. If earnings are mostly rate-cycle windfall, the stock should be valued like a cyclical bank near peak profitability rather than a compounding franchise.

Bladex’s capital allocation must retain enough earnings to support a larger balance sheet while still returning excess capital to shareholders without weakening the bank. Owners benefit only if loan growth compounds per-share value; growth funded by excessive leverage or under-retention would increase fragility.

All standing thesis claims
Original report summary

its specialized Latin American trade-finance franchise can keep turning scarce U.S.-dollar funding and regional credit knowledge into profitable, well-capitalized loan growth after the current rate cycle normalizes.

Evidence assessed Nov 3, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Bladex

Where the evidence on Bladex stands: Holding on the latest evidence (Nov 3, 2026). Of its 5 thesis points, 4 strengthening and 1 holding.

Bull case: what the evidence supports

  • Latin American importers, exporters, and financial institutions continue to need specialized U.S.-dollar trade finance that Bladex can supply better than more generalist local banks or global banks with shifting regional appetite.

    sec.gov ↗

  • Bladex’s ability to maintain ample U.S.-dollar liquidity is a core advantage because clients value dependable funding through regional liquidity cycles, not just headline loan pricing.

    sec.gov ↗

  • Management must keep emerging-market credit risk disciplined enough that balance-sheet expansion does not turn into a credit-loss cycle.

    sec.gov ↗

  • The recent earnings step-up must prove to be more than a temporary benefit from higher interest rates; Bladex needs relationship-based pricing and funding discipline to preserve spreads as rates normalize.

    sec.gov ↗

  • Bladex’s capital allocation must retain enough earnings to support a larger balance sheet while still returning excess capital to shareholders without weakening the bank.

    sec.gov ↗

Bear case: what would count against it

  • Large global banks materially re-expand Latin American trade-finance books and win the same multinational and bank clients at lower spreads.

    sec.gov ↗

  • A ratings downgrade or country-risk shock raises Bladex’s wholesale dollar funding cost enough that trade-finance spreads no longer compensate for risk.

    sec.gov ↗

  • A concentrated borrower, bank counterparty, or country exposure in Latin America deteriorates before reserves are built.

    sec.gov ↗

Thesis-Break Engine

What has broken in Bladex’s thesis

Each break OptimistFi flagged on Bladex, dated — with what has historically followed the same kind of break across the market, not a forecast for Bladex.

  • Sharp drawdowncondition set before this filing

    Across all companies, this kind of break has happened 15,428 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Foreign issuer material report (6-K).

    Bladex filed an SEC report on 2026-10-28: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  2. Mixed
    Foreign issuer material report (6-K).

    Bladex filed an SEC report on 2026-10-27: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  3. Mixed
    Foreign issuer material report (6-K).

    Bladex filed an SEC report on 2026-09-16: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Large global banks materially re-expand Latin American trade-finance books and win the same multinational and bank clients at lower spreads.
  • A ratings downgrade or country-risk shock raises Bladex’s wholesale dollar funding cost enough that trade-finance spreads no longer compensate for risk.
  • A concentrated borrower, bank counterparty, or country exposure in Latin America deteriorates before reserves are built.
  • Federal Reserve easing compresses asset yields faster than Bladex can lower funding costs.
  • Management pursues asset growth faster than capital generation, increasing leverage into a weaker credit cycle.

BLX news

Loading headlines…

Financial statements

BLX income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

BLX: quick answers

What is BLX's short interest?
As of October 30, 2026, 409,145 BLX shares were sold short, down 35.3% from the count before. At the stock's average daily volume that is 2.1 days to cover. FINRA publishes the count twice a month. BLX short interest history
Have members of Congress traded BLX?
1 trade in BLX has been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed BLX trade
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.